Chemotherapy with mitomycin-C, epidoxorubicin and vinblastine in CMF failing breast cancer patients

P. Pronzato, D. Amoroso, G. Bertelli, P. Queirolo, M. R. Sertoli, R. Rosso

Research output: Contribution to journalArticle

Abstract

Since most patients with breast cancer are treated with CMF as first line chemotherapy (usually in the adjuvant setting), schedules with alternative drugs are needed for the metastatic disease. In this study a new combination of Mitomycin, Epidoxorubicin and Vinblastine was employed in a group of 24 patients with metastatic breast cancer. A response rate of 37.5% was observed with a mild to moderate toxicity.

Original languageEnglish
Pages (from-to)1743-1745
Number of pages3
JournalAnticancer Research
Volume10
Issue number6
Publication statusPublished - 1990

Keywords

  • chemotherapy
  • CMF
  • metastatic breast cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Chemotherapy with mitomycin-C, epidoxorubicin and vinblastine in CMF failing breast cancer patients'. Together they form a unique fingerprint.

  • Cite this